Fibrolamellar patients are invited and encouraged to participate in the Natural History Study of Rare Solid Tumors, currently underway at the National Cancer Institute (NCI) in Bethesda, Maryland. The purpose of this study is to better understand how rare solid tumors develop and grow. Natural history studies like this will help researchers learn more about fibrolamellar carcinoma (FLC) and other rare cancers and help shape the design and development of clinical trials to test new treatment options.
How it works: The Natural History Study of Rare Solid Tumors collects medical information and tissue samples from patients with rare solid tumors, such as FLC. The study also collects important information about the patient’s quality of life, such as pain levels or the impact the tumor has on physical functioning, called patient reported outcomes (PROs). Unlike a clinical treatment trial, this natural history study does not test the safety or efficacy of a new therapy. Instead, it compiles information from patients and their medical records to better understand the “history” or progression of rare cancers over time. Researchers will use this natural history study data to identify disease trends and get new ideas on how to treat rare cancers like fibrolamellar. Patients who are involved in this study can help accelerate the development of new treatments by giving researchers critical information they need to make progress.
Participation requirements and patient benefits: Importantly, given the current realities of COVID-19 and social distancing, patients can participate in this natural history study from home without needing to travel. Participating patients will be asked to send a saliva sample to NCI, and will be asked to fill out questionnaires about their medical history, their family’s medical history, and how having a rare tumor impacts their life. With permission, NCI will collect medical records and imaging from patients or their physicians for review by the study team. NCI will also collect samples of patients’ tumors that may be available from prior biopsies or surgeries. All participants will receive a follow-up form from NCI approximately once a year to record any changes in their health. As an additional benefit, participating patients and their doctors will be notified by the NCI research team if any clinically actionable mutations associated with their disease are discovered in the study’s genetic testing process.
This study is being carried out by NCI’s MyPART (My Pediatric and Adult Rare Tumor Network), a group that drives research across a range of pediatric, adolescent, and young adult rare tumors. MyPART and the Natural History Study of Rare Solid Tumors are part of NCI’s “Cancer Moonshot” portfolio. In 2016, President Obama launched the national “Moonshot” initiative to accelerate cancer research efforts and eliminate barriers to progress by broadening access to important data and facilitating collaboration among researchers, patients, advocacy organizations, and pharmaceutical companies. To support these efforts, Congress passed the 21st Century Cures Act in December 2016, authorizing $1.8 billion in funding over 7 years, including $195 million funding for the NCI in fiscal year 2020. Participation of fibro patients in this study creates a valuable opportunity to focus some of that sizeable “Moonshot” research effort on fibrolamellar carcinoma.
To learn more about this opportunity to contribute to research, click here to view additional details about the study and a series of frequently asked questions.